Anticancer activity of novel copper(II) complex with a schiff-base ligand on in vitro and in vivo osteosarcoma cancer models

BALSA, L.M.; SOLERNO L; RODRIGUEZ M.R.; ANA C. GONZÁLEZ BARÓ; ALONSO D; GARONA J; LEON I.E

Congreso; Reunión Conjunta (SAIC-SAI-AAFE-NANOMED.ar); 2021

Osteosarcoma (OS) is the most common bone malignant tumor, affecting mainly children and young adults. Cisplatin has been effective for the treatment of different solid tumors, including OS. However, cisplatin treatment often results in the development of chemoresistance and several side effects, leading to therapeutic failure. In this sense, copper compounds have shown to be potentially effective as antitumor agents, attracting increasing interest as alternatives to usually employed platinum derived drugs.The aim of this work is to evaluate the in vitro and in vivo antitumoral activity against MG-63 cells of the nitrate salt of a novel Cu(II) cationic complex containing a tridentate hydrazone ligand, Cu(HL) for short.Cytotoxic activity on MG-63 cell line was evaluated in 2D (monolayer) and 3D (spheroids) models. Cu(HL) significantly reduced cell viability after 24 h treatment in both models (IC50 2D: 1.98 ± 0.51 µM; 3D: 9.05 ± 1.0 µM) (p